Ligand to acquire APEIRON Biologics for $100 million
Ligand Pharmaceuticals has entered into a definitive agreement to acquire APEIRON Biologics, which holds royalty rights to QARZIBA (dinutuximab beta) for the treatment of high-risk neuroblastoma, for $100 million in cash. In addition, Ligand will pay …